» Articles » PMID: 24646516

Diurnal Patterns of Soluble Amyloid Precursor Protein Metabolites in the Human Central Nervous System

Overview
Journal PLoS One
Date 2014 Mar 21
PMID 24646516
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

The amyloid-β (Aβ) protein is diurnally regulated in both the cerebrospinal fluid and blood in healthy adults; circadian amplitudes decrease with aging and the presence of cerebral Aβ deposits. The cause of the Aβ diurnal pattern is poorly understood. One hypothesis is that the Amyloid Precursor Protein (APP) is diurnally regulated, leading to APP product diurnal patterns. APP in the central nervous system is processed either via the β-pathway (amyloidogenic), generating soluble APP-β (sAPPβ) and Aβ, or the α-pathway (non-amyloidogenic), releasing soluble APP-α (sAPPα). To elucidate the potential contributions of APP to the Aβ diurnal pattern and the balance of the α- and β- pathways in APP processing, we measured APP proteolytic products over 36 hours in human cerebrospinal fluid from cognitively normal and Alzheimer's disease participants. We found diurnal patterns in sAPPα, sAPPβ, Aβ40, and Aβ42, which diminish with increased age, that support the hypothesis that APP is diurnally regulated in the human central nervous system and thus results in Aβ diurnal patterns. We also found that the four APP metabolites were positively correlated in all participants without cerebral Aβ deposits. This positive correlation suggests that the α- and β- APP pathways are non-competitive under normal physiologic conditions where APP availability may be the limiting factor that determines sAPPα and sAPPβ production. However, in participants with cerebral Aβ deposits, there was no correlation of Aβ to sAPP metabolites, suggesting that normal physiologic regulation of cerebrospinal fluid Aβ is impaired in the presence of amyloidosis. Lastly, we found that the ratio of sAPPβ to sAPPα was significantly higher in participants with cerebral Aβ deposits versus those without deposits. Therefore, the sAPPβ to sAPPα ratio may be a useful biomarker for cerebral amyloidosis.

Citing Articles

P-tau217 and other blood biomarkers of dementia: variation with time of day.

Monica C, Revell V, Atzori G, Laban R, Skene S, Heslegrave A Transl Psychiatry. 2024; 14(1):373.

PMID: 39271655 PMC: 11399374. DOI: 10.1038/s41398-024-03084-7.


A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's Disease.

Galasko D, Farlow M, Lucey B, Honig L, Elbert D, Bateman R Alzheimers Res Ther. 2024; 16(1):151.

PMID: 38970127 PMC: 11225352. DOI: 10.1186/s13195-024-01490-z.


A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer's Disease.

Galasko D, Farlow M, Lucey B, Honig L, Elbert D, Bateman R medRxiv. 2024; .

PMID: 38562783 PMC: 10984053. DOI: 10.1101/2024.03.20.24304638.


Role of sleep in neurodegeneration: the consensus report of the 5th Think Tank World Sleep Forum.

Ferini-Strambi L, Liguori C, Lucey B, Mander B, Spira A, Videnovic A Neurol Sci. 2023; 45(2):749-767.

PMID: 38087143 DOI: 10.1007/s10072-023-07232-7.


The metabolism of human soluble amyloid precursor protein isoforms is quantifiable by a stable isotope labeling-tandem mass spectrometry method.

Dobrowolska Zakaria J, Bateman R, Lysakowska M, Khatri A, Jean-Gilles D, Kennedy M Sci Rep. 2022; 12(1):14985.

PMID: 36056033 PMC: 9440206. DOI: 10.1038/s41598-022-18869-3.


References
1.
Skovronsky D, Moore D, Milla M, Doms R, Lee V . Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network. J Biol Chem. 2000; 275(4):2568-75. DOI: 10.1074/jbc.275.4.2568. View

2.
Gabelle A, Roche S, Geny C, Bennys K, Labauge P, Tholance Y . Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid. Brain Res. 2010; 1357:175-83. DOI: 10.1016/j.brainres.2010.08.022. View

3.
Vassar R, Bennett B, Kahn S, Mendiaz E, Denis P, Teplow D . Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999; 286(5440):735-41. DOI: 10.1126/science.286.5440.735. View

4.
Alexopoulos P, Tsolakidou A, Roselli F, Arnold A, Grimmer T, Westerteicher C . Clinical and neurobiological correlates of soluble amyloid precursor proteins in the cerebrospinal fluid. Alzheimers Dement. 2011; 8(4):304-11. DOI: 10.1016/j.jalz.2011.04.009. View

5.
Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J . Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry. 2008; 15(2):138-45. DOI: 10.1038/mp.2008.84. View